Does Blue Cross Blue Shield Cover Eliquis?

How BCBS Formulary Coverage Works for Eliquis

Blue Cross Blue Shield is not a single insurer. It is a federation of 34 independently operated companies that license the BCBS brand, and each affiliate maintains its own formulary 1. That means your neighbor's BCBS plan in Michigan may place Eliquis on a different tier than your BCBS plan in Georgia.

The Tier System

Most BCBS commercial plans use a four- or five-tier structure. Tier 1 holds generics. Tier 2 holds preferred brands. Tier 3 holds non-preferred brands. Specialty tiers (4 or 5) carry the highest cost-sharing. Eliquis lands on Tier 2 or Tier 3 in the vast majority of BCBS formularies, according to a 2023 analysis of 48 commercial formularies published in the Journal of Managed Care & Specialty Pharmacy 2.

Why Tier Placement Matters

A Tier 2 placement typically means a flat copay of $35 to $50 per fill. Tier 3 often shifts to coinsurance (25% to 40% of the drug's list price), which can push monthly costs above $150 before any copay assistance. The retail list price for a 30-day supply of Eliquis 5 mg twice daily was approximately $620 as of early 2026 3.

Checking Your Specific Plan

The fastest way to confirm your tier: log in to your BCBS member portal and search "apixaban" or "Eliquis" in the formulary lookup tool. If you do not have portal access, call the number on the back of your card and ask the pharmacy benefits representative for the formulary tier, any quantity limits, and whether prior authorization applies.

FDA-Approved Indications That BCBS Typically Covers

BCBS plans generally cover Eliquis for all five of its FDA-approved indications. Coverage denials tend to arise when the prescribed use falls outside these labeled indications or when required documentation is missing.

Atrial Fibrillation

The most common reason patients receive Eliquis is stroke prevention in nonvalvular atrial fibrillation (AFib). The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared to warfarin (hazard ratio 0.79, 95% CI 0.66 to 0.95, P=0.01) with a 31% reduction in major bleeding 4. This evidence base makes AFib the indication least likely to trigger a coverage barrier.

Deep Vein Thrombosis and Pulmonary Embolism

Eliquis is approved for treatment of DVT and PE, as well as for reducing the risk of recurrent DVT and PE after initial therapy. The AMPLIFY trial (N=5,395) showed apixaban was noninferior to standard enoxaparin/warfarin therapy for recurrent VTE, with 73% less major bleeding (0.6% vs. 1.8%, P<0.001) 5.

Post-Surgical DVT Prophylaxis

For DVT prevention after hip or knee replacement surgery, some BCBS affiliates require prior authorization. The ADVANCE-3 trial (N=5,407) established apixaban's superiority over enoxaparin for this indication 6. If your plan requires prior authorization for surgical prophylaxis, your orthopedic surgeon's office typically submits this before discharge.

Prior Authorization and Step Therapy Requirements

Not every BCBS plan requires prior authorization for Eliquis, but enough do that it is worth understanding the process before you arrive at the pharmacy.

When Prior Authorization Applies

Prior authorization is most common for post-surgical prophylaxis, off-label uses, and certain Medicare Advantage plans. A 2024 survey of managed care pharmacy directors found that 22% of commercial plans and 38% of Medicare Advantage plans required some form of utilization management for direct oral anticoagulants (DOACs) 7.

Step Therapy Considerations

Step therapy (also called "fail first") means the plan requires you to try a less expensive drug before it will cover the requested one. For anticoagulants, step therapy is uncommon but not extinct. A small number of BCBS legacy plans still include a warfarin step-edit, though the American College of Cardiology and American Heart Association 2019 AFib guidelines list DOACs (including apixaban) as preferred over warfarin for most patients with nonvalvular AFib 8.

If your plan imposes a warfarin step-edit, your prescriber can submit a formulary exception request citing the ACC/AHA guideline recommendation. The 2019 focused update states: "For patients with AF who are appropriate for anticoagulation with a DOAC, a DOAC is recommended over warfarin" (Class I, Level of Evidence A) 8.

How Long Approval Takes

Most BCBS affiliates process standard prior authorization requests within 48 to 72 hours. Urgent requests (for example, a hospitalized patient who needs anticoagulation at discharge) can be expedited to a 24-hour turnaround. If denied, you have the right to a plan-level appeal and, if that fails, an external independent review.

Out-of-Pocket Cost Estimates by Plan Type

Your actual cost for Eliquis depends on your plan type, your tier, and whether you use a copay assistance program.

Commercial (Employer-Sponsored) Plans

Most commercially insured patients pay $35 to $90 per month for Eliquis at a network pharmacy. Plans with coinsurance rather than flat copays can run higher. A 2023 IQVIA analysis of commercial claims found a median out-of-pocket cost of $47 per fill for apixaban 9.

BCBS Medicare Advantage Plans

Medicare Advantage plans from BCBS vary widely. During the initial coverage phase, expect copays of $42 to $100 per month. Once you enter the coverage gap (the "donut hole"), your share increases. The Inflation Reduction Act of 2022 capped annual out-of-pocket prescription drug spending at $2,000 beginning in 2025, which benefits patients taking high-cost brand medications like Eliquis 10.

BCBS Federal Employee Program (FEP)

The Blue Cross Blue Shield Federal Employee Program, which covers approximately 5.3 million federal employees, retirees, and dependents, lists Eliquis on its preferred brand tier with a $60 copay for a 90-day mail-order supply 11. This makes it one of the more cost-effective BCBS options for Eliquis access.

ACA Marketplace Plans

If you purchased a BCBS plan through the Health Insurance Marketplace, your tier and copay depend on the metal level (Bronze, Silver, Gold, Platinum). Gold and Platinum plans typically offer lower copays for brand-name drugs. Silver plans with cost-sharing reductions (for households earning below 250% of the federal poverty level) may also reduce your drug cost-sharing.

How to Lower Your Eliquis Cost with BCBS

Even with insurance, a brand-name anticoagulant can strain a household budget. Several strategies can reduce what you pay.

Bristol-Myers Squibb / Pfizer Copay Card

The manufacturer copay assistance program can reduce your cost to as low as $10 per month for eligible commercially insured patients. This card does not apply to government-funded insurance (Medicare, Medicaid, Tricare, VA). Maximum annual benefit is $6,400 per calendar year. You can enroll at the manufacturer's website or through your prescriber's office.

90-Day Mail Order

Many BCBS plans offer a mail-order pharmacy benefit that provides a 90-day supply for two copays instead of three. For a drug you take daily and indefinitely, this translates to a 33% savings on copay costs over the course of a year.

Formulary Exception Requests

If Eliquis sits on a non-preferred tier in your plan, your prescriber can submit a formulary exception request arguing that the preferred alternative is medically inappropriate for you. Valid clinical reasons include a history of warfarin-related bleeding, labile INR control, inability to comply with INR monitoring, or documented drug-drug interactions with warfarin. The ACC/AHA guidelines provide the clinical backing for these requests 8.

Patient Assistance Programs

Uninsured or underinsured patients who do not qualify for the copay card may be eligible for the Bristol-Myers Squibb Patient Assistance Foundation, which provides Eliquis at no cost to qualifying individuals. Household income must fall at or below 300% of the federal poverty level.

Eliquis vs. Other Anticoagulants on BCBS Formularies

Your BCBS plan may prefer a different DOAC over Eliquis, or it may offer comparable coverage for multiple options.

Xarelto (Rivarelbaan)

Rivaroxaban is the other widely prescribed DOAC. The ROCKET AF trial (N=14,264) showed rivaroxaban was noninferior to warfarin for stroke prevention in AFib, though it did not demonstrate superiority in the intention-to-treat analysis 12. Some BCBS formularies place rivaroxaban and apixaban on the same tier. Others prefer one over the other based on rebate negotiations.

Warfarin

Warfarin is a Tier 1 generic costing $4 to $10 per month. It remains clinically appropriate for patients with mechanical heart valves or antiphospholipid syndrome. For nonvalvular AFib, the ACC/AHA guidelines favor DOACs over warfarin in most patients 8.

Savaysa (Edoxaban) and Pradaxa (Dabigatran)

Edoxaban (ENGAGE AF-TIMI 48, N=21,105) and dabigatran (RE-LY, N=18,113) are also FDA-approved for AFib. Both appear on BCBS formularies, though they are prescribed less frequently than apixaban or rivaroxaban. A network meta-analysis published in The Lancet found that apixaban had the most favorable combined efficacy and safety profile among DOACs for stroke prevention 13.

What to Do If BCBS Denies Coverage

A denial is not the final word. The appeals process exists for a reason, and anticoagulant denials are frequently overturned when clinical documentation supports the request.

Step 1: Read the Denial Letter

BCBS is required to send a written explanation that includes the specific reason for denial and your appeal rights. Common denial reasons include missing prior authorization, incorrect diagnosis code, or the plan preferring an alternative drug.

Step 2: Internal Appeal

Your prescriber submits a letter of medical necessity along with supporting clinical records. Include the specific FDA-approved indication, relevant trial data (ARISTOTLE for AFib, AMPLIFY for VTE), and any patient-specific factors that make alternatives inappropriate. BCBS affiliates must respond to internal appeals within 30 days for standard requests and 72 hours for urgent cases.

Step 3: External Review

If the internal appeal is denied, you can request an external independent review. An independent physician reviewer examines the case. Under the Affordable Care Act, external review decisions are binding on the insurer 14.

When to Involve Your State Insurance Commissioner

If you believe BCBS is not following its own formulary rules or is improperly applying utilization management, your state Department of Insurance can investigate. This is a separate process from the clinical appeals pathway and can run in parallel.

Clinical Monitoring While Taking Eliquis

Unlike warfarin, Eliquis does not require routine INR blood testing. This is one of its practical advantages and a reason many prescribers and patients prefer it.

Routine Lab Work

The ACC recommends a complete blood count and renal function panel (serum creatinine, estimated GFR) at baseline and at least annually 8. Patients with chronic kidney disease (eGFR 15 to 29 mL/min) should receive the reduced dose of 2.5 mg twice daily per the FDA label. Eliquis is contraindicated in patients on dialysis, though limited pharmacokinetic data exist in this population 3.

Dose Adjustments

The standard AFib dose is 5 mg twice daily. A reduced dose of 2.5 mg twice daily applies when at least two of the following three criteria are met: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. These criteria come directly from the ARISTOTLE trial enrollment criteria and the FDA label 4.

Drug Interactions to Discuss with Your Prescriber

Strong dual inhibitors of CYP3A4 and P-glycoprotein (ketoconazole, itraconazole, ritonavir, clarithromycin) increase apixaban exposure and may require dose reduction. Strong dual inducers (rifampin, carbamazepine, phenytoin) reduce apixaban levels and should generally be avoided in combination 3.

Patients taking Eliquis should report any new bleeding symptoms (unusual bruising, blood in urine or stool, prolonged nosebleeds) to their prescriber within 24 hours. Carry a card or medical alert identification noting that you take an anticoagulant, as this information is critical in emergency settings.